Cargando…

Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes

INTRODUCTION: Restless legs syndrome (RLS) affects 5–15% of adults, but is often unrecognized and consequently misdiagnosed. The International Restless Legs Scale (IRLS) has been developed and validated to assess the severity of RLS. Currently, the most common treatment for RLS is levodopa, but this...

Descripción completa

Detalles Bibliográficos
Autor principal: Winlow, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321653/
https://www.ncbi.nlm.nih.gov/pubmed/22496675
_version_ 1782228969101197312
author Winlow, William
author_facet Winlow, William
author_sort Winlow, William
collection PubMed
description INTRODUCTION: Restless legs syndrome (RLS) affects 5–15% of adults, but is often unrecognized and consequently misdiagnosed. The International Restless Legs Scale (IRLS) has been developed and validated to assess the severity of RLS. Currently, the most common treatment for RLS is levodopa, but this may lead to augmentation of symptoms. Pramipexole has been developed as an alternative treatment for patients diagnosed with RLS. AIMS: The objective of this article is to review the evidence of the effectiveness of pramipexole for the clinical management of patients with RLS. EVIDENCE REVIEW: There is clear evidence that pramipexole reduces the leg movements associated with RLS, as measured by improvements in both the IRLS and the Clinical Global Impression (CGI) score. There is also moderate evidence that the drug improves sleep quality. Pramipexole clearly improves the anxiety and depression often associated with RLS. Augmentation may be associated with pramipexole treatment, but the evidence is contradictory and augmentation may be more associated with patients pretreated with levodopa or with patients with primary RLS rather than those with secondary RLS. Pramipexole therapy appears to be well tolerated, with only mild-to-moderate adverse events reported. OUTCOMES SUMMARY: Pramipexole reduces leg movements in RLS, and is well tolerated. Further investigation is required to confirm the preliminary evidence that pramipexole restores normal sleep architecture and restores a normal quality of life in patients with RLS. Health economic studies would be valuable in demonstrating the true impact of pramipexole on the social burden of RLS.
format Online
Article
Text
id pubmed-3321653
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33216532012-04-11 Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes Winlow, William Core Evid Outcomes Review INTRODUCTION: Restless legs syndrome (RLS) affects 5–15% of adults, but is often unrecognized and consequently misdiagnosed. The International Restless Legs Scale (IRLS) has been developed and validated to assess the severity of RLS. Currently, the most common treatment for RLS is levodopa, but this may lead to augmentation of symptoms. Pramipexole has been developed as an alternative treatment for patients diagnosed with RLS. AIMS: The objective of this article is to review the evidence of the effectiveness of pramipexole for the clinical management of patients with RLS. EVIDENCE REVIEW: There is clear evidence that pramipexole reduces the leg movements associated with RLS, as measured by improvements in both the IRLS and the Clinical Global Impression (CGI) score. There is also moderate evidence that the drug improves sleep quality. Pramipexole clearly improves the anxiety and depression often associated with RLS. Augmentation may be associated with pramipexole treatment, but the evidence is contradictory and augmentation may be more associated with patients pretreated with levodopa or with patients with primary RLS rather than those with secondary RLS. Pramipexole therapy appears to be well tolerated, with only mild-to-moderate adverse events reported. OUTCOMES SUMMARY: Pramipexole reduces leg movements in RLS, and is well tolerated. Further investigation is required to confirm the preliminary evidence that pramipexole restores normal sleep architecture and restores a normal quality of life in patients with RLS. Health economic studies would be valuable in demonstrating the true impact of pramipexole on the social burden of RLS. Dove Medical Press 2005 2005-03-31 /pmc/articles/PMC3321653/ /pubmed/22496675 Text en © 2005 Dove Medical Press Limited. All rights reserved
spellingShingle Outcomes Review
Winlow, William
Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
title Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
title_full Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
title_fullStr Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
title_full_unstemmed Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
title_short Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
title_sort pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
topic Outcomes Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321653/
https://www.ncbi.nlm.nih.gov/pubmed/22496675
work_keys_str_mv AT winlowwilliam pramipexoleinrestlesslegssyndromeanevidencebasedreviewofitseffectivenessonclinicaloutcomes